The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 07, 2024
Filed:
Dec. 07, 2018
Applicants:
Helmholtz-zentrum Fur Infektionsforschung Gmbh, Braunschweig, DE;
Medizinische Hochschule Hannover, Hannover, DE;
Inventors:
Lars Zender, Braunschweig, DE;
Torsten Wuestefeld, Braunschweig, DE;
Assignee:
MEDIZINISCHE HOCHSCHULE HANNOVER, Hannover, DE;
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/407 (2015.01); A61K 31/00 (2006.01); A61K 31/352 (2006.01); A61K 31/353 (2006.01); A61K 31/416 (2006.01); A61K 31/4709 (2006.01); A61K 31/519 (2006.01); A61K 31/52 (2006.01); A61K 31/53 (2006.01); A61K 31/5377 (2006.01); A61K 31/713 (2006.01); A61M 1/02 (2006.01); C07C 237/42 (2006.01); C07D 213/75 (2006.01); C07D 231/54 (2006.01); C07D 231/56 (2006.01); C07D 311/30 (2006.01); C07D 311/36 (2006.01); C07D 401/12 (2006.01); C07D 407/12 (2006.01); C07D 473/38 (2006.01); C07D 487/04 (2006.01); C12M 3/00 (2006.01); C12N 5/071 (2010.01); C12N 15/00 (2006.01); C12N 15/113 (2010.01); A61M 1/36 (2006.01); C12N 15/09 (2006.01); C12N 15/10 (2006.01); C12N 15/11 (2006.01); C12N 15/66 (2006.01); C12P 19/34 (2006.01);
U.S. Cl.
CPC ...
A61K 35/407 (2013.01); A61K 31/00 (2013.01); A61K 31/352 (2013.01); A61K 31/353 (2013.01); A61K 31/416 (2013.01); A61K 31/4709 (2013.01); A61K 31/519 (2013.01); A61K 31/52 (2013.01); A61K 31/53 (2013.01); A61K 31/5377 (2013.01); A61K 31/713 (2013.01); A61M 1/02 (2013.01); C07C 237/42 (2013.01); C07D 213/75 (2013.01); C07D 231/54 (2013.01); C07D 231/56 (2013.01); C07D 311/30 (2013.01); C07D 311/36 (2013.01); C07D 401/12 (2013.01); C07D 407/12 (2013.01); C07D 473/38 (2013.01); C07D 487/04 (2013.01); C12M 3/00 (2013.01); C12N 5/067 (2013.01); C12N 15/00 (2013.01); C12N 15/1137 (2013.01); C12Y 207/11024 (2013.01); A61M 1/36 (2013.01); C12N 15/09 (2013.01); C12N 15/102 (2013.01); C12N 15/11 (2013.01); C12N 15/66 (2013.01); C12N 2310/00 (2013.01); C12N 2310/14 (2013.01); C12N 2310/141 (2013.01); C12N 2310/531 (2013.01); C12N 2810/00 (2013.01); C12P 19/34 (2013.01);
Abstract
The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.